前列腺癌离体γH2AX放疗敏感性检测:患者间与患者内异质性
研究采用离体γH2AX焦点检测法评估未经治疗前列腺癌标本的肿瘤细胞放疗敏感性,发现21例病理 confirmed 肿瘤样本的残余γH2AX焦点-剂量斜率在0.82至3.17焦点/Gy之间,患者间异质性高于患者内异质性,且斜率与Gleason评分、PSA及肿瘤分期无相关性。
要点
- 前列腺癌患者间放疗敏感性异质性明显,高于患者内异质性。
- 残余γH2AX焦点斜率与Gleason评分、PSA、肿瘤分期无相关性。
- 单次活检足以估算残余γH2AX均值并涵盖患者内异质性。
核心结论
- 前列腺癌患者间肿瘤细胞放疗敏感性异质性显著且高于患者内异质性,支持进一步开发离体γH2AX检测作为个体化治疗生物标志物。
研究设计与样本
- 从未治疗前列腺癌患者切除标本在培养基中培养24小时,离体照射后24小时固定,计数残余γH2AX焦点并计算剂量反应斜率。
- 患者内异质性通过3至7个不同活检样本研究,共纳入21例病理 confirmed 肿瘤样本。
主要发现
- 21例病理 confirmed 肿瘤样本的残余γH2AX焦点斜率范围为0.82至3.17焦点/Gy。
- 斜率值与Gleason评分(p=0.37)、前列腺特异性抗原(p=0.48)及肿瘤分期(p=0.89)无相关性。
- 方差分析显示9例患者中仅1例不同肿瘤部位活检差异有统计学意义。
- 方差成分分析表明患者间变异性高于患者内变异性。
- Bootstrap模拟研究显示一次活检足以估算每个剂量水平的残余γH2AX均值并涵盖患者内异质性。
临床怎么用
- 离体γH2AX检测可评估前列腺癌放疗敏感性,患者间异质性支持其作为个体化治疗生物标志物的进一步开发。
- 单次活检即可代表患者整体残余γH2AX水平,简化检测流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The aim of the study is to assess inter-patient and intra-patient heterogeneity in tumour cell radiosensitivity using the ex vivo γH2AX assay in prostate cancer specimens. METHODS: Excised specimens from untreated prostate cancer patients were cultivated 24h in media, irradiated ex vivo and fixed after 24h. Residual γH2AX foci were counted and the slope of the dose response was calculated. Intra-patient heterogeneity was studied from three to seven different biopsies. RESULTS: In pathology-confirmed tumour samples from 21 patients the slope of residual γH2AX foci and radiation dose showed a substantial heterogeneity ranging from 0.82 to 3.17 foci/Gy. No correlation was observed between the slope values and the Gleason score (p=0.37), prostate specific antigen (p=0.48) and tumour stage (p=0.89). ANOVA indicated that only in 1 out of 9 patients, biopsies from different tumour locations yielded statistically significant differences. Variance component analysis indicated higher inter-patient than intra-patient variability. Bootstrap simulation study demonstrated that one biopsy is sufficient to estimate the mean value of residual γH2AX per dose level and account for intra-patient heterogeneity. CONCLUSIONS: In prostate cancer inter-patient heterogeneity in tumour cell radiation sensitivity is pronounced and higher than intra-patient heterogeneity supporting the further development of the γH2AX ex vivo assay as a biomarker for individualized treatment.
引用
- De-Colle C, Yaromina A, Hennenlotter J, et al. Ex vivo γH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. Radiother Oncol. 2017. PMID: 28919005. doi:10.1016/j.radonc.2017.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。